Trial Profile
An Open-Label, Randomised Phase 1b/2 Study Of PF-04691502 In Combination With Letrozole Compared With Letrozole Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Early Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs PF 4691502 (Primary) ; Letrozole
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Jul 2022 This trial has been completed in Spain as reported by European Clinical Trials Database record.
- 29 Nov 2012 Planned End Date changed from 1 Apr 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
- 06 Sep 2012 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.